Tuesday, December 17, 2019 6:54:46 PM
Mellowmood77,
You are 100% correct that AMARIN'S PR on FRIDAY 12-13-2019, concerning sales projection's for the end of 2019 and 2020 caused this downturn from $26 to $21.... lower guidence killed us.... always look to the future...
AMARIN tried to under promise (sandbag) and over deliver in their forecast.... if they had stated $140 to $150 mil 4th quarter projection which would be 20% over 3rd quarter for 2019, and $800-900 mil (see HDG projection ) for 2020 which equates TO 80-90% over 2019, we would have been fine.... as MELLOWMOOD77 stated, the market looks at forward guidence and JT stating $650-700M indicates only 55-60% growth, the same as last year projection.... considering we should get almost all of the generic sales, which SAM posts each week,that alone get us to $800m...I emailed ELISABETH Sunday and Mon. before CC, to have JT consider changing his projections, stating that over the weekend that these new projections reflect normal consistent sales patterns.... No response...
That would have made OPPENHEIMER'S and the other four analysts projections mute.... see how they stayed within their earlier reports of sales projections...they easily created doubt and made their $2-3 mil 2022-2023 sales projection look solid....
Add that the Generic Case settlement hearing was also on Monday and the non settlement makes Amarin look vulnerable.... you can deal with one issue at a time, but when you have to deal with multiple issues, see what transpires.... Amarin is now on the defense and not the offense...
Take time to E-MAIL Elisabeth giving your imput.....
You are 100% correct that AMARIN'S PR on FRIDAY 12-13-2019, concerning sales projection's for the end of 2019 and 2020 caused this downturn from $26 to $21.... lower guidence killed us.... always look to the future...
AMARIN tried to under promise (sandbag) and over deliver in their forecast.... if they had stated $140 to $150 mil 4th quarter projection which would be 20% over 3rd quarter for 2019, and $800-900 mil (see HDG projection ) for 2020 which equates TO 80-90% over 2019, we would have been fine.... as MELLOWMOOD77 stated, the market looks at forward guidence and JT stating $650-700M indicates only 55-60% growth, the same as last year projection.... considering we should get almost all of the generic sales, which SAM posts each week,that alone get us to $800m...I emailed ELISABETH Sunday and Mon. before CC, to have JT consider changing his projections, stating that over the weekend that these new projections reflect normal consistent sales patterns.... No response...
That would have made OPPENHEIMER'S and the other four analysts projections mute.... see how they stayed within their earlier reports of sales projections...they easily created doubt and made their $2-3 mil 2022-2023 sales projection look solid....
Add that the Generic Case settlement hearing was also on Monday and the non settlement makes Amarin look vulnerable.... you can deal with one issue at a time, but when you have to deal with multiple issues, see what transpires.... Amarin is now on the defense and not the offense...
Take time to E-MAIL Elisabeth giving your imput.....
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
